Molecular Formula | C18H21N3O3S |
Molar Mass | 359.44 |
Density | 1.33±0.1 g/cm3(Predicted) |
Melting Point | 99-100° (dec) |
Boling Point | 603.9±65.0 °C(Predicted) |
Flash Point | 152.266°C |
Solubility | DMSO (Slightly), Methanol (Slightly) |
Vapor Presure | 0mmHg at 25°C |
Appearance | Solid |
Color | Light Brown to Very Dark Brown |
pKa | 9.57±0.10(Predicted) |
Storage Condition | Inert atmosphere,Store in freezer, under -20°C |
Stability | Hygroscopic |
Refractive Index | 1.505 |
Use | Used as an anti-ulcer drug |
Hazard Symbols | Xi - Irritant |
Risk Codes | 36/38 - Irritating to eyes and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S37/39 - Wear suitable gloves and eye/face protection |
pure white or light yellow to white powder, tasteless. mp140 ~ 141 degrees C (decomposition). Very soluble in water, methanol, soluble in ethanol, chloroform or ethyl acetate, insoluble in ether or hexane. Rapid decomposition in acidic solution, stable in alkaline solution.
2,3-= methyl-4-nitropyridine-N-oxide was dissolved in dichloromethane, trifluoroacetic anhydride was added dropwise, and reflux was added. Excess trifluoroacetic anhydride was distilled off and methylene chloride was added. After cooling to room temperature, triethylamine and 2-mercaptobenzimidazole were added and the reaction was complete. The solvent was distilled off, ethanol and water were added, stirred, and filtered to give 2-[(3-methyl-4-nitro-2-pyridyl) methyl] Sulfur] -1H-benzimidazole. The compound and potassium carbonate are suspended in 3-methoxy-1-propanol and isopropanol, treatment gave 2-[[3-methyl -4-(3-methoxypropoxy)-2-pyridyl] methyl] Thio]-1H-benzimidazole. The compound is dissolved in dichloromethane, and a dichloromethane solution of M-chloroperbenzoic acid is added dropwise, and the resulting product is treated with sodium hydroxide, dichloromethane, ammonia water, acetone and the like.
developed by Eisai, Japan, was first launched in Japan in 1998 and was approved by the FDA for marketing in the United States in August 1999. Proton pump inhibitors. Treatment of gastroesophageal acid reflux (GERD), duodenal ulcer. This includes treatment of daytime and nighttime heartburn and other symptoms associated with gastro-esophageal reflux disease (GERD). Rabeprazole sodium is a new type of proton pump inhibitor, which can be used in the treatment of acid related diseases, such as peptic ulcer, gastroesophageal reflux disease, Ehrlich syndrome and so on. Its anti-gastric acid secretion activity is greater than the original proton pump inhibitor omeprazole. Compared with omeprazole, rabeprazole inhibits H /K-ATPase more strongly, and the inhibition can be restored; For the treatment of acid-related diseases, such as peptic ulcer, gastroesophageal reflux disease, zhuoyi Ehrlich syndrome, etc.